Compare AbCellera Biologics Inc (ABCL) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs ProShares Ultra Semiconductors — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while ProShares Ultra Semiconductors trades at $89.34. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals.
| ABCL | USD | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $8.12 | $113.53 |
52-Week Low | $2.78 | $37.63 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
USD stock trades at $90.36, up 3.26% with a bearish technical signal from moving averages. The company announced a $0.14 dividend payable June 30, 2026. Recent news highlights institutional interest with JPMorgan Chase increasing its stake by 325% in Q3 2026. Technical indicators show neutral oscillators but bearish momentum with key support at $85 and resistance at $93.
The stock faces headwinds from bearish technical momentum despite recent price gains. Institutional accumulation and dividend payments provide support, but the overall technical picture suggests caution. Semiconductor sector volatility remains a key risk factor for this leveraged ETF.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
